Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97. (Record no. 23029268)

MARC details
000 -LEADER
fixed length control field 01593 a2200349 4500
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250516165038.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 201404s 0 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1744-7666
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1517/14656566.2013.826190
Source of number or code doi
040 ## - CATALOGING SOURCE
Original cataloging agency NLM
Language of cataloging eng
Transcribing agency NLM
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Havrdova, Eva
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Date of production, publication, distribution, manufacture, or copyright notice 20140403
245 00 - TITLE STATEMENT
Title Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97.
Medium [electronic resource]
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. Expert opinion on pharmacotherapy
Date of publication, distribution, etc. Oct 2013
300 ## - PHYSICAL DESCRIPTION
Extent 2145-56 p.
Other physical details digital
500 ## - GENERAL NOTE
General note Publication Type: Journal Article; Comment
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Female
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Fumarates
General subdivision therapeutic use
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Immunosuppressive Agents
General subdivision therapeutic use
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Male
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Multiple Sclerosis, Relapsing-Remitting
General subdivision drug therapy
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Peptides
General subdivision therapeutic use
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Hutchinson, Michael
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Kurukulasuriya, Nuwan C
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Raghupathi, Kartik
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Sweetser, Marianne T
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Dawson, Katherine T
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Gold, Ralf
773 0# - HOST ITEM ENTRY
Title Expert opinion on pharmacotherapy
Related parts vol. 14
-- no. 15
-- p. 2145-56
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://doi.org/10.1517/14656566.2013.826190">https://doi.org/10.1517/14656566.2013.826190</a>
Public note Available from publisher's website

No items available.